Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

At Woman's Hospital in Baton Rouge, lawmakers from Washington D.C. celebrated the start of their "Newborn Essential Support ...

New Delhi, Jan 9 (PTI) Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital ...

In this article, we are going to take a look at where Eli ... diabetes treatment options. The company boasts of a robust pipeline of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. Eli ...

GLP-1 drugs, initially developed to treat diabetes, help people lose weight ... Retatrutide is currently being developed by Eli Lilly & Co., and is being tested in ongoing clinical trials.

Ozempic is approved for type 2 diabetes, while its counterpart, Wegovy, is approved for treating obesity. Both are made by Novo Nordisk. Eli Lilly also offers a diabetes ... Drug Administration (FDA).

They’re also more likely to experience decreased quality of care and increased barriers to self-management. Type 1.5 diabetes is found in adults over 30 and is often mistaken for type 2 ...

More than 170 bags were donated to the scheme over the festive period [BBC] A scheme that provided female street sex workers with care kits over the festive period has been so successful it will ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow compounding pharmacies to continue churning out knockoffs to the popular diabetes and obesity drugs.